Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 5/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL626138 | 0.85 | TRPV3 (0.44) | TRPV3NR1I2KCNA5KDM4EKCNE1 | |
| SCHEMBL624598 | 0.84 | TRPV3 (0.52) | TRPV3NR1I2KCNA5KDM4EKCNE1 | |
| SCHEMBL626384 | 0.83 | TRPV3 (0.43) | TRPV3SMN1; SMN2NR1I2KCNA5KDM4E | |
| SCHEMBL626095 | 0.82 | TRPV3 (0.46) | TRPV3NR1I2KCNA5KDM4EKCNE1 | |
| SCHEMBL625818 | 0.80 | TRPV3 (0.43) | TRPV3SMN1; SMN2NR1I2KDM4ECYP1A2 | |
| SCHEMBL625133 | 0.78 | TRPV3 (0.48) | TRPV3SMN1; SMN2NR1I2KCNA5FFAR2 | |
| SCHEMBL14893921 | 0.78 | TRPV3 (0.46) | TRPV3NR1I2CYP3A4 | |
| SCHEMBL14895928 | 0.75 | TRPV3 (0.48) | TRPV3SMN1; SMN2NR1I2KCNA5TP53 | |
| SCHEMBL626330 | 0.75 | TRPV3 (0.48) | TRPV3NR1I2ALDH1A1 | |
| SCHEMBL624769 | 0.74 | TRPV3 (0.55) | TRPV3SMN1; SMN2NR1I2KCNA5KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2603490-A1 | NOVEL TRPV3 MODULATORS | AbbVie Inc. (US) | 2013-06-19 | — | — | EP | claimed |
| US-20130150409-A1 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-06-13 | — | — | US | claimed |
| WO-2012019315-A1 | NOVEL TRPV3 MODULATORS | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | WO | claimed |
| US-9156788-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2015-10-13 | — | — | US | disclosed |
| EP-2771322-A2 | NOVEL TRPV3 MODULATORS | AbbVie Inc. (US) | 2014-09-03 | — | — | EP | disclosed |
| US-8772500-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772499-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20140080803-A1 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2014-03-20 | — | — | US | disclosed |
| EP-2603490-A1 | NOVEL TRPV3 MODULATORS | AbbVie Inc. (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20130150409-A1 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130131036-A1 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2013062964-A2 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-05-02 | — | — | WO | disclosed |
| WO-2013062966-A2 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-05-02 | — | — | WO | disclosed |
| WO-2012019315-A1 | NOVEL TRPV3 MODULATORS | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131036-A1 | NOVEL TRPV3 MODULATORS | TRPV3, TRPV4, TRPV5 | TRPV3 1/4885SMN1; SMN2 3680/4885NR1I2 210/4885 |
| US-20130150409-A1 | NOVEL TRPV3 MODULATORS | TRPV3, TRPV4, TRPV5 | TRPV3 1/4885SMN1; SMN2 3887/4885NR1I2 219/4885 |
| US-20140080803-A1 | NOVEL TRPV3 MODULATORS | TRPV3, TRPV4, TRPV5 | TRPV3 1/4885SMN1; SMN2 3605/4885NR1I2 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.